8-K: ZimVie Reports Improved Q2 Profitability Amidst Pending $19.00 Per Share Acquisition by ARCHIMED

ZimVie Inc. announced its second quarter 2025 financial results, showing improved profitability metrics, alongside the definitive agreement to be acquired by ARCHIMED for $19.00 per share in cash, expected to close by year-end 2025.

Summary

• Net sales from continuing operations for the second quarter of 2025 were $116.7 million, a slight decrease of 0.1% on a reported basis and 2.1% in constant currency compared to Q2 2024.
• Net loss from continuing operations significantly improved to $(3.8) million in Q2 2025, an improvement of $5.7 million from a net loss of $(9.6) million in Q2 2024.
• Net loss margin improved by 490 basis points to (3.3)% of net sales in Q2 2025.
• Adjusted net income from continuing operations increased by $3.6 million to $7.2 million in Q2 2025.
• GAAP diluted EPS from continuing operations was $(0.14), an improvement from $(0.35) in Q2 2024.
• Adjusted diluted EPS from continuing operations was $0.26 in Q2 2025, up from $0.13 in Q2 2024.
• Adjusted EBITDA from continuing operations increased by $1.6 million to $17.5 million in Q2 2025, with an Adjusted EBITDA margin of 15.0%, up 150 basis points.
• ZimVie entered into a definitive agreement on July 21, 2025, to be acquired by an affiliate of ARCHIMED for $19.00 in cash per share.
• The acquisition is expected to close by year-end 2025, subject to stockholder and regulatory approvals.
• Upon completion, ZimVie will become a privately held company, and its common stock will be delisted from NASDAQ.
• Fiscal 2025 guidance has been withdrawn due to the pending transaction, and no conference call will be hosted for the second quarter results.

Sentiment

Score: 8

Explanation: The definitive acquisition agreement at $19.00 per share provides a clear and positive outcome for shareholders, offering a premium and a defined exit. The underlying financial results, while showing a slight revenue dip, demonstrate significant improvements in profitability metrics (net loss, adjusted net income, adjusted EBITDA), indicating operational progress prior to the acquisition announcement.

Positives

• Net loss from continuing operations improved by $5.7 million, narrowing to $(3.8) million in Q2 2025 from $(9.6) million in Q2 2024.
• Net loss margin improved by 490 basis points to (3.3)% in Q2 2025.
• Adjusted net income increased by $3.6 million to $7.2 million in Q2 2025.
• Adjusted diluted EPS rose to $0.26 in Q2 2025 from $0.13 in Q2 2024.
• Adjusted EBITDA increased by $1.6 million to $17.5 million in Q2 2025.
• Adjusted EBITDA margin improved by 150 basis points to 15.0% in Q2 2025.
• The definitive acquisition agreement by ARCHIMED for $19.00 per share provides a clear cash exit for shareholders.

Negatives

• Net sales from continuing operations slightly decreased by 0.1% on a reported basis and 2.1% in constant currency in Q2 2025 compared to Q2 2024.
• The company has withdrawn its fiscal 2025 guidance due to the pending acquisition, removing future financial visibility.

Risks

• The proposed acquisition may not be completed in a timely manner or at all.
• Failure to receive required approval of the proposed transaction by stockholders.
• Failure to satisfy or waive various other conditions to the consummation of the proposed transaction, including regulatory approvals.
• Possibility of competing offers or acquisition proposals for ZimVie.
• Occurrence of any event, change, or circumstance that could lead to the termination of the definitive agreement, potentially requiring a termination fee.
• The pendency of the proposed transaction may affect the ability to attract, motivate, or retain key executives and employees.
• The pendency of the proposed transaction may affect the ability to maintain relationships with customers, suppliers, and other business counterparties.
• The pendency of the proposed transaction may impact operating results and business generally.
• The proposed transaction may divert management's attention from ongoing business operations.
• The stock price may decline significantly if the proposed transaction is not consummated.
• Dependence on new product development, technological advances, and innovation.
• Shifts in product category or regional sales mix of products and services.
• Supply and prices of raw materials and products, including impacts from tariffs.
• Pricing pressures from competitors, customers, dental practices, and insurance providers.
• Changes in customer demand for products and services caused by demographic changes or other factors.
• Challenges relating to changes in and compliance with governmental laws and regulations affecting U.S. and international businesses, including more stringent requirements for regulatory clearance of products.
• Competition in the dental implant market.
• Impact of healthcare reform measures and reductions in reimbursement levels by third-party payors.
• Cost containment efforts sponsored by government agencies, legislative bodies, the private sector, and healthcare group purchasing organizations, including volume-based procurement in China.
• Dependence on a limited number of suppliers for key raw materials and outsourced activities.
• Ability to obtain and maintain adequate intellectual property protection.
• Breaches or failures of information technology systems or products, including by cyberattack, unauthorized access, or theft.
• Ability to retain the independent agents and distributors who market products.
• Ability to attract, retain, and develop highly skilled employees.
• Effect of mergers and acquisitions on relationships with customers, suppliers, and lenders, and on operating results and businesses generally.
• A determination by the Internal Revenue Service that the 2022 distribution of common stock by Zimmer Biomet Holdings, Inc. or certain related transactions should be treated as taxable transactions.
• Ability to form and implement alliances.
• Changes in tax obligations arising from tax reform measures or examinations by tax authorities.
• Product liability, intellectual property, and commercial litigation losses.
• Changes in general industry and market conditions, including domestic and international growth rates.
• Changes in general domestic and international economic conditions, including inflation, interest rate, and currency exchange rate fluctuations.
• Effects of global pandemics and other adverse public health developments on the global economy, business, operations, suppliers, and customers, including the deferral of elective procedures and ability to collect accounts receivable.
• Impact of ongoing financial and political uncertainty on countries in the Euro zone on the ability to collect accounts receivable.

Future Outlook

ZimVie has withdrawn its fiscal 2025 guidance due to the pending acquisition by ARCHIMED. The transaction is expected to close by year-end 2025, subject to customary closing conditions including stockholder and regulatory approvals. Upon completion, ZimVie will become a privately held company, and its common stock will no longer be publicly traded.

Management Comments

• "Our results this quarter reflect the strength of our people and their unwavering commitment to executing our strategy and delivering for our customers and stakeholders."
• "I would like to thank our entire team for their continued hard work and dedication."

Industry Context

ZimVie operates in the global dental implant market, a segment of the broader life sciences industry focused on tooth replacement and restoration. The acquisition by ARCHIMED, a private equity firm specializing in healthcare, signals a potential shift towards private ownership for companies in this space, possibly driven by a desire for long-term strategic development away from public market pressures or a consolidation trend within the medical device sector. The company's focus on dental implants, biomaterials, and digital workflow solutions aligns with ongoing trends in dentistry towards advanced, integrated solutions.

Stakeholder Impact

• Shareholders: Will receive $19.00 in cash per share upon the closing of the acquisition, providing a defined return and liquidity.
• Employees: The pendency of the transaction may impact the company's ability to attract, motivate, or retain key executives and employees.
• Customers and Suppliers: The pendency of the transaction may affect the company's ability to maintain relationships with its customers and suppliers.

Next Steps

• ZimVie's stockholders must approve the proposed acquisition.
• Receipt of applicable regulatory approvals for the acquisition.
• ZimVie's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, is expected to be filed.
• The acquisition by ARCHIMED is expected to close by year-end 2025.

Key Dates

Recommendation

The definitive agreement for ZimVie to be acquired by ARCHIMED for $19.00 per share in cash caps the potential upside for the stock. Investors currently holding shares should hold to realize the acquisition value, while new investors would only consider an arbitrage play if the stock trades significantly below the offer price, factoring in the risks of the deal not closing.

Keywords

Dental Implants, Life Sciences, Biomaterials, Digital Workflow Solutions, Dental Tooth Replacement, Dental Restoration, Medical Devices, Acquisition, Merger, ARCHIMED, ZimVie, ZIMV, Healthcare